Kinins and peptide receptors

References

Alhenc-Gelas, F., Bouby, N., Richer, C., Potier, L., Roussel, R., and Marre, M. (2011). Kinins as therapeutic agents in cardiovascular and renal diseases. Curr. Pharm. Des. 17, 2654–2662.10.2174/138161211797416002Suche in Google Scholar

Anderson, S., Rennke, H.G., and Brenner, B.M. (1986). Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J. Clin. Invest. 77, 1993–2000.10.1172/JCI112528Suche in Google Scholar

Avogaro, A., Albiero, M., Menegazzo, L., de Kreutzenberg, S., and Fadini, G.P. (2011). Endothelial dysfunction in diabetes: the role of reparatory mechanisms. Diabetes Care 34 Suppl 2, S285–S290.10.2337/dc11-s239Suche in Google Scholar

Bonjour, J.P., Peters, G., Chomety, F., and Regoli, D. (1967). Renal effects of val 5-angiotensin 11-amide, vasopressin and diuretics in the rat, as influenced by water diuresis and by ethanol anesthesia. Eur. J. Pharmacol. 2, 88–105.10.1016/0014-2999(67)90030-1Suche in Google Scholar

Brunner, H., Desaulles, P.A., Regoli, D., and Gross F. (1962). Renin content and excretory function of the kidney in rats with experimental hypertension. Am. J. Physiol. 202, 795–799.10.1152/ajplegacy.1962.202.4.795Suche in Google Scholar PubMed

Calo, G., Guerrini, R., Rizzi, A., Salvadori, S., and Regoli, D. (2000). Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br. J. Pharmacol. 129, 1261–1283.10.1038/sj.bjp.0703219Suche in Google Scholar PubMed PubMed Central

Camarda, V., Rizzi, A., Ruzza, C., Zucchini, S., Marzola, G., Marzola, E., Guerrini, R., Salvadori, S., Reinscheid, R.K., Regoli, D., et al. (2009). In vitro and in vivo pharmacological characterization of the neuropeptide s receptor antagonist [D-Cys(tBu)5]neuropeptide S. J. Pharmacol. Exp. Ther. 328, 549–555.10.1124/jpet.108.143867Suche in Google Scholar PubMed PubMed Central

Campbell, D.J., Kladis, A., and Duncan A.M. (1993). Bradykinin peptides in kidney, blood, and other tissues of the rat. Hypertension 21, 155–165.10.1161/01.HYP.21.2.155Suche in Google Scholar

Carey, R.M. and Padia S.H. (2008). Angiotensin AT2 receptors: control of renal sodium excretion and blood pressure. Trends Endocrinol. Metab. 19, 84–87.10.1016/j.tem.2008.01.003Suche in Google Scholar PubMed

Carretero, O.A. and Scicli, A.G. (1991). Local hormonal factors (intracrine, autocrine, and paracrine) in hypertension. Hypertension 18, I58–I69.10.1161/01.HYP.18.3_Suppl.I58Suche in Google Scholar PubMed

Casas, J.P., Chua, W., Loukogeorgakis, S., Vallance, P., Smeeth, L., Hingorani, A.D. and MacAllister, R.J. (2005). Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366, 2026–2033.10.1016/S0140-6736(05)67814-2Suche in Google Scholar

Cheng, J., Zhang, W., Zhang, X., Han, F., Li, X., He, X., Li, Q., and Chen, J. (2014). Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern. Med. 174, 773–785.10.1001/jamainternmed.2014.348Suche in Google Scholar

Cooper, M.E. (1998). Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 352, 213–219.10.1016/S0140-6736(98)01346-4Suche in Google Scholar

Cooper, M.E. (2001). ACE and diabetes. In: ACE Inhibitors. P. D’Orléans-Juste and G.E. Plante eds. (Basel: Birkhäuser), pp. 177–184.10.1007/978-3-0348-7579-0_14Suche in Google Scholar

Couture, R. and Girolami, J.P. (2004). Putative roles of kinin receptors in the therapeutic effects of angiotensin 1-converting enzyme inhibitors in diabetes mellitus. Eur. J. Pharmacol. 500, 467–485.10.1016/j.ejphar.2004.07.045Suche in Google Scholar PubMed

Cushman, D.W., Cheung, H.S., Sabo, E.F., and Ondetti, M.A. (1977). Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry 16, 5484–5491.10.1021/bi00644a014Suche in Google Scholar PubMed

Daskalopoulou, S.S., Rabi, D.M., Zarnke, K.B., Dasgupta, K., Nerenberg, K., Cloutier, L., Gelfer, M., Lamarre-Cliche, M., Milot, A., Bolli, P., et al. (2015). The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can. J. Cardiol. 31, 549–568.10.1016/j.cjca.2015.02.016Suche in Google Scholar PubMed

de Gasparo, M., Catt, K.J., Inagami, T., Wright, J.W., and Unger, T. (2000). International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 52, 415–472.Suche in Google Scholar

De Vriese, A.S., Verbeuren, T.J., Van de Voorde, J., Lameire, N.H., and Vanhoutte, P.M. (2000). Endothelial dysfunction in diabetes. Br. J. Pharmacol. 130, 963–974.10.1038/sj.bjp.0703393Suche in Google Scholar PubMed PubMed Central

Ferrari, R. (2006). ACE-inhibition for secondary prevention of cardiovascular events – should we change our recommendation after PEACE? Cardiovasc. Drugs Ther. 20, 11–12.Suche in Google Scholar

Ferreira, S.H. (1965). A Bradykinin-potentiating factor (BPF) present in the venom of Bothrops Jararca. Br. J. Pharmacol. Chemother. 24, 163–169.10.1111/j.1476-5381.1965.tb02091.xSuche in Google Scholar PubMed PubMed Central

Ferreira, S.H. and Vane, J.R. (1967). Half-lives of peptides and amines in the circulation. Nature 215, 1237–1240.10.1038/2151237a0Suche in Google Scholar PubMed

Furchgott, R.F. and Bhadrakom, S. (1953). Reactions of strips of rabbit aorta to epinephrine, isopropylarterenol, sodium nitrite and other drugs. J. Pharmacol. Exp. Ther. 108, 129–143.Suche in Google Scholar

Gavras, I. and Gavras, H. (2001). The role of ACE inhibition in heart failure. In: ACE Inhibitors. P. D’Orléans-Juste and G.E. Plante, eds. (Basel: Birkhäuser), pp. 77–79.10.1007/978-3-0348-7579-0_6Suche in Google Scholar

Girolami, J.P., Blaes, N., Bouby, N., and Alhenc-Gelas, F. (2014). Genetic manipulation and genetic variation of the kallikrein-kinin system: impact on cardiovascular and renal diseases. Prog. Drug Res. 69, 145–196.10.1007/978-3-319-06683-7_6Suche in Google Scholar PubMed

Gross, F., Regoli, D., and Schaechtelin, G. (1963). Renin content and blood concentration of renin. In: Hormones and the Kidney. Proceedings of the 89th Meeting of the Society for Endocrinology held at Cambridge, September 1962. Society for Endocrinology. and P.C. Williams, ed. (London; New York: Academic Press), pp. 293–300.Suche in Google Scholar

Hadi, H.A. and Suwaidi, J.A. (2007). Endothelial dysfunction in diabetes mellitus. Vasc. Health Risk Manag. 3, 853–876.Suche in Google Scholar

Hilgenfeldt, U., Linke, R., Riester, U., Konig, W., and Breipohl, G. (1995). Strategy of measuring bradykinin and kallidin and their concentration in plasma and urine. Anal. Biochem. 228, 35–41.10.1006/abio.1995.1311Suche in Google Scholar PubMed

James, P.A., Oparil, S., Carter, B.L., Cushman, W.C., Dennison-Himmelfarb, C., Handler, J., Lackland, D.T., LeFevre, M.L., MacKenzie, T.D., Ogedegbe, O., et al. (2014). 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). J. Am. Med. Assoc. 311, 507.10.1001/jama.2013.284427Suche in Google Scholar PubMed

Lamarre-Cliche, M. and Larochelle, P. (2001). Evaluative and epidemiological approaches of ACE therapy. In: ACE Inhibitors. P. D’Orléans-Juste and G.E. Plante, eds. (Basel: Birkhäuser), pp. 47–70.10.1007/978-3-0348-7579-0_5Suche in Google Scholar

Marceau, F. and Regoli, D. (2004). Bradykinin receptor ligands: therapeutic perspectives. Nat. Rev. Drug Discov. 3, 845–852.10.1038/nrd1522Suche in Google Scholar PubMed

Marceau, F. and Regoli, D. (2008). Therapeutic options in inflammatory bowel disease: experimental evidence of a beneficial effect of kinin B1 receptor blockade. Br. J. Pharmacol. 154, 1163–1165.10.1038/bjp.2008.233Suche in Google Scholar PubMed PubMed Central

Ondetti, M.A., Rubin, B., and Cushman, D.W. (1977). Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 196, 441–444.10.1126/science.191908Suche in Google Scholar PubMed

Paul, M., Poyan Mehr, A., and Kreutz, R. (2006). Physiology of local renin-angiotensin systems. Physiol. Rev. 86, 747–803.10.1152/physrev.00036.2005Suche in Google Scholar PubMed

Ravid, M., Brosh, D., Levi, Z., Bar-Dayan, Y., Ravid, D., and Rachmani R. (1998). Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann. Intern. Med. 128, 982–988.10.7326/0003-4819-128-12_Part_1-199806150-00004Suche in Google Scholar

Regoli, D. (1959). Su alcuni aspetti della farmacologia della idroclorotiazide. Siena: University of Siena. Lepetit Prize for the Best Thesis of the University of Siena.Suche in Google Scholar

Regoli, D. and Barabé, J. (1980). Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 32, 1–46.Suche in Google Scholar

Regoli, D. and Gobeil, F., Jr. (2015). Critical insights into the beneficial and protective actions of the kallikrein-kinin system. Vascul. Pharmacol. 64, 1–10.10.1016/j.vph.2014.12.003Suche in Google Scholar

Regoli, D. and Vane, J.R. (1964). A sensitive method for the assay of angiotensin. Br. J. Pharmacol. Chemother. 23, 351–359.10.1111/j.1476-5381.1964.tb01591.xSuche in Google Scholar

Regoli, D. and Vane, J.R. (1966). The continuous estimation of angiotensin formed in the circulation of the dog. J. Physiol. 183, 513–531.10.1113/jphysiol.1966.sp007881Suche in Google Scholar

Regoli, D., Riniker, B., and Brunner, H. (1963). The enzymatic degradation of various angiotensin II derivatives by serum, plasma or kidney homogenate. Biochem. Pharmacol. 12, 637–646.10.1016/0006-2952(63)90039-XSuche in Google Scholar

Regoli, D., Park, W.K., and Rioux, F. (1974). Pharmacology of angiotensin. Pharmacol. Rev. 26, 69–123.Suche in Google Scholar

Regoli, D., Rhaleb, N.E., Dion, S., and Drapeau, G. (1990). New selective bradykinin receptor antagonists and bradykinin B2 receptor characterization. Trends Pharmacol. Sci. 11, 156–161.10.1016/0165-6147(90)90067-ISuche in Google Scholar

Regoli, D., Boudon, A., and Fauchere, J.L. (1994). Receptors and antagonists for substance P and related peptides. Pharmacol. Rev. 46, 551–599.Suche in Google Scholar

Regoli, D., Plante, G.E., and Gobeil, F., Jr. (2012). Impact of kinins in the treatment of cardiovascular diseases. Pharmacol. Ther. 135, 94–111.10.1016/j.pharmthera.2012.04.002Suche in Google Scholar PubMed

Ruschitzka, F. and Taddei, S. (2012). Angiotensin-converting enzyme inhibitors: first-line agents in cardiovascular protection? Eur. Heart J. 33, 1996–1998.10.1093/eurheartj/ehs108Suche in Google Scholar PubMed

Schaechtelin, G., Baechtold, N., Haefeli, L., Regoli, D., Gaudry-Paredes, A., and Peters, G. (1968). A renin-inactivating system in rat plasma. Am. J. Physiol. 215, 632–636.10.1152/ajplegacy.1968.215.3.632Suche in Google Scholar PubMed

Sindone, A., Erlich, J., Perkovic, V., Suranyi, M., Newman, H., Lee, C., Barin, E., and Roger, S.D. (2013). ACEIs for cardiovascular risk reduction--have we taken our eye off the ball? Aust. Fam. Physician 42, 634–638.Suche in Google Scholar

Skeggs, L.T., Jr., Kahn, J.R., and Shumway, N.P. (1956). The preparation and function of the hypertensin-converting enzyme. J. Exp. Med. 103, 295–299.10.1084/jem.103.3.295Suche in Google Scholar PubMed PubMed Central

van Vark, L.C., Bertrand, M., Akkerhuis, K.M., Brugts, J.J., Fox, K., Mourad, J.J., and Boersma, E. (2012). Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur. Heart J. 33, 2088–2097.10.1093/eurheartj/ehs075Suche in Google Scholar PubMed PubMed Central

Vane, J.R. (1969). The release and fate of vaso-active hormones in the circulation. Br. J. Pharmacol. 35, 209–242.10.1111/j.1476-5381.1969.tb07982.xSuche in Google Scholar

Vane, J. (1993). Control of the circulation by endothelial mediators. Inaugural G.B. West Memorial Lecture. Int. Arch. Allergy Immunol. 101, 333–345.10.1159/000236474Suche in Google Scholar

Vane, J.R. (1994). The Croonian Lecture, 1993: the endothelium: maestro of the blood circulation. Phil. Trans. R. Soc. B 343, 225–246.10.1098/rstb.1994.0023Suche in Google Scholar

Yang, H.Y. and Erdos, E.G. (1967). Second kininase in human blood plasma. Nature 215, 1402–1403.10.1038/2151402a0Suche in Google Scholar

Zanchetti, A. (1986). Volhard lecture: sympatho-renal interactions and blood pressure control. J. Hypertens. Suppl 4, S4–S13.Suche in Google Scholar

Zatz, R. and Brenner, B.M. (1986). Pathogenesis of diabetic microangiopathy. The hemodynamic view. Am. J. Med. 80, 443–453.10.1016/0002-9343(86)90719-9Suche in Google Scholar

Zatz, R., Dunn, B.R., Meyer, T.W., Anderson, S., Rennke, H.G. and Brenner, B.M. (1986). Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J. Clin. Invest. 77, 1925–1930.10.1172/JCI112521Suche in Google Scholar PubMed PubMed Central